ARTICLE | Clinical News
Nuplazid: Ph II started
November 17, 2016 2:33 PM UTC
Acadia began the double-blind, placebo-controlled, international Phase II ADVANCE trial to evaluate once-daily oral Nuplazid in combination with ongoing antipsychotic treatment for 26 weeks in about 3...
BCIQ Company Profiles
BCIQ Target Profiles